Press Releases April 20, 2026 06:30 AM

BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB913 Million in 2026

KANZHUN LIMITED advances strong shareholder value through extensive share repurchases in 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (BOSS Zhipin), a company listed on Nasdaq and Hong Kong stock exchanges, announced April 17th repurchases of 349,698 shares using RMB17.0 million. Year-to-date 2026, the company has invested over RMB913 million in repurchasing shares, reiterating its dedication to enhancing shareholder value.

BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB913 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED repurchased 349,698 shares on April 17, 2026, using RMB17.0 million.
  • The total amount spent on share repurchases in 2026 has exceeded RMB913 million.
  • The share repurchase program highlights the company's commitment to returning capital to shareholders.

BEIJING, April 20, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB17.0 million to repurchase 349,698 ordinary shares on April 17. Year-to-date in 2026, the Company has deployed over RMB913 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued large-scale share repurchases may limit available capital for operational growth or strategic investments.
  • Market conditions or regulatory changes could impact future buyback activities.
  • Overemphasis on buybacks might mask underlying business performance challenges.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026